BackAltimmune Overview
Altimmune Inc

Altimmune Target Price

Where could ALT trade next? Consensus target price: $6.3.

Get informed when a big investor buys or sells

+ Follow

Share Price

$3.07

Average Target Price

$6.25103.6% upside

2 analysts in the last 4 months

High: $10 | Low: $2.5

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-06-22Leerink PartnersThomas Smith$10225.7% upsideOpen
2026-04-24Goldman SachsCorinne Johnson$2.518.6% downsideOpen
2026-01-27Barclays$20551.5% upsideOpen
2024-04-02H.C. WainwrightPatrick Trucchio$12290.9% upsideOpen
2022-12-01Goldman Sachs$20551.5% upsideOpen
2022-11-11JMP Securities$26746.9% upsideOpen
2022-08-31Jefferies$351040.1% upsideOpen
2022-08-30Piper SandlerYasmeen Rahimi$25714.3% upsideOpen
2022-08-17H.C. Wainwright$501528.7% upsideOpen

Altimmune (ALT) FAQ

Altimmune's target price stands at $6.3. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $6.3 for ALT implies 103.6% upside versus today's price ($3.07). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Altimmune's target price evolved across reporting periods, while the comparison chart places ALT next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Altimmune's reading of $6.3 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.